Drug intelligence / Profile preview

ExtraGraft

Development stage: Unknown
Lead developer: Silvestre Labs
Modality: Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Implant

Overview

ExtraGraft is a bone substitute biomaterial developed by Silvestre Labs for the treatment of bone defects and orthopedic reconstruction. It is a composite material consisting of 75% bovine hydroxyapatite and 25% type I collagen. The hydroxyapatite component provides an osteoconductive scaffold with physicochemical properties similar to human bone, facilitating cell migration and bone remodeling. The collagen component enhances the material's handling properties, allowing it to be presented as moldable cylinders for surgical implantation. It is designed to be placed directly into bone voids to support new bone formation.

Brand names: ExtraGraft
Other names: Extra Graft

Beyond the preview

Go deeper on ExtraGraft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExtraGraft.

Explore the full profile